4-benzyloxymethylpyridine | 107622-88-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-benzyloxymethylpyridine
• 英文别名: 4-benzyloximethyl-pyridine；4-Benzyloxymethyl-pyridin；4-(Phenylmethoxymethyl)pyridine
• CAS: 107622-88-8
• 化学式: C₁₃H₁₃NO
• 分子量: 199.252
• InChiKey: KMVZLVVXSUWGBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-benzyloxymethylpyridine 在 对甲苯磺酰氯 、 间氯过氧苯甲酸 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 69.33h， 生成 4-((Benzyloxy)methyl)pyridin-2-amine
  参考文献：
  名称：

  Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5′-phosphatase 2 (SHIP2)

  摘要：

  Novel 4-substituted 2-pyridin-2-ylamides were developed using in-silico ligand-based drug design (LBDD) in an attempt to identify inhibitors of SH2-containing 5'-inositol phosphatase 2 (SHIP2), which is implicated in insulin-resistant type 2 diabetes. Among the compounds synthesized, N-[4-(4-chlorobenzyloxy) pyridin-2-yl]-2-(2,6-difluorophenyl)- acetamide (CPDA, 4a) was identified as a potent SHIP2 inhibitor. CPDA was found to enhance in vitro insulin signaling through the Akt pathway more efficiently than the previously reported SHIP2 inhibitor AS1949490, and ameliorated abnormal glucose metabolism in diabetic (db/db) mice. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.01.014
• 作为产物：
  描述：

  4-吡啶甲醇 在 氢氧化钾 、 18-冠醚-6 、 三乙胺 作用下， 以 苯 为溶剂， 反应 7.0h， 生成 4-benzyloxymethylpyridine
  参考文献：
  名称：

  Synthesis of alkyl heteryl ethers from acetates under interphase catalysis conditions in a liquid/solid system

  摘要：

  DOI：

  10.1007/bf02290610

文献信息

• Combined Iron/Hydroxytriazole Dual Catalytic System for Site Selective Oxidation Adjacent to Azaheterocycles
  作者：Julian C. Cooper、Chaosheng Luo、Ryohei Kameyama、Jeffrey F. Van Humbeck

  DOI：10.1021/jacs.7b12864

  日期：2018.1.31

  This report details a new method for site-selective methylene oxidation adjacent to azaheterocycles. A dual catalysis approach, utilizing both an iron Lewis acid and an organic hydroxylamine catalyst, proved highly effective. We demonstrate that this method provides complementary selectivity to other known catalytic approaches and represents an improvement over current heterocycle-selective reactions

  本报告详细介绍了一种与氮杂杂环相邻的位点选择性亚甲基氧化的新方法。双催化方法，利用铁路易斯酸和有机羟胺催化剂，证明是非常有效的。我们证明该方法为其他已知的催化方法提供了互补的选择性，并代表了对目前依赖化学计量活化的杂环选择性反应的改进。
• Dual-Ligand Catalyst for the Nondirected C–H Olefination of Heteroarenes
  作者：Guangrong Meng、Zhen Wang、Hau Sun Sam Chan、Nikita Chekshin、Zhen Li、Peng Wang、Jin-Quan Yu

  DOI：10.1021/jacs.3c01631

  日期：——

  allow them to be used as limiting reagents, the reaction conditions are incompatible with electron-deficient heteroarenes. Herein we report a dual-ligand catalyst that enables Pd(II)-catalyzed nondirected C–H olefination of heteroarenes without using a large excess of substrate. In general, the use of 1–2 equiv of substrates was sufficient to obtain synthetically useful yields. The reactivity was rationalized

  Pd(II) 催化的杂芳烃非定向 C-H 官能化是一个重大挑战，原因如下：缺电子杂环的反应活性差以及路易斯碱性氮原子的无效配位。使用钯催化的现有方法通常使用大量过量的杂环底物来克服这些障碍。尽管芳烃非定向官能化的最新进展使其可以用作限制试剂，但反应条件与缺电子杂芳烃不相容。在此，我们报道了一种双配体催化剂，该催化剂能够在不使用大量过量底物的情况下实现 Pd(II) 催化的杂芳烃非定向 C-H 烯化。一般来说，使用 1-2 当量的底物足以获得合成有用的产率。两种配体之间的协同作用使反应活性合理化：双齿吡啶-吡啶酮配体促进C-H裂解；单齿杂环底物作为第二配体形成对芳烃具有高亲和力的阳离子 Pd(II) 络合物。所提出的双配体合作得到了 X 射线、动力学和控制实验相结合的支持。
• Suzuki, Pharmaceutical Bulletin, 1956, vol. 4, p. 211,212,214
  作者：Suzuki

  DOI：——

  日期：——
• COMPOSES POUR LEUR UTILISATION EN IMAGERIE ET NOTAMMENT POUR LE DIAGNOSTIC DE MALADIES NEURO-DEGENERATIVES
  申请人：Centre National de la Recherche Scientifique

  公开号：EP3515912B1

  公开（公告）日：2020-10-14
• Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5′-phosphatase 2 (SHIP2)
  作者：Yoshinori Ichihara、Ryohei Fujimura、Hiroshi Tsuneki、Tsutomu Wada、Kentaro Okamoto、Hiroaki Gouda、Shuichi Hirono、Kenji Sugimoto、Yuji Matsuya、Toshiyasu Sasaoka、Naoki Toyooka

  DOI：10.1016/j.ejmech.2013.01.014

  日期：2013.4

  Novel 4-substituted 2-pyridin-2-ylamides were developed using in-silico ligand-based drug design (LBDD) in an attempt to identify inhibitors of SH2-containing 5'-inositol phosphatase 2 (SHIP2), which is implicated in insulin-resistant type 2 diabetes. Among the compounds synthesized, N-[4-(4-chlorobenzyloxy) pyridin-2-yl]-2-(2,6-difluorophenyl)- acetamide (CPDA, 4a) was identified as a potent SHIP2 inhibitor. CPDA was found to enhance in vitro insulin signaling through the Akt pathway more efficiently than the previously reported SHIP2 inhibitor AS1949490, and ameliorated abnormal glucose metabolism in diabetic (db/db) mice. (C) 2013 Elsevier Masson SAS. All rights reserved.